

## PRIOR AUTHORIZATION PROGRAM FORM

Simponi® (Golimumab)

## Instructions:

Date Received:

- 1. Section 1 to be completed by Plan Member / Patient
- 2. Section 2 to be completed by Physician (expenses incurred by the completion of this form is at plan member's expense)
- 3. Section 3 to be completed by Pharmacist

Please fax completed form to NexgenRx Formulary Management to 1-877-639-4369 or mail to 145 The West Mall P.O. Box 110 U, Toronto, Ontario, M8Z-5M4

Section 1: To be completed	by Patient											
Member's Name: (Last , First )	Card ID Number:											
Patient's Name: (Last, First)	Patient's Dat	Patient's Date of Birth (dd/mm/yy)			Relationship to Member (please circle) PATIENT							
					Employee Spouse Dependent CODE							
Results of this request to be common	unicated to:								I .			
☐ Pharmacy ☐ Patient / Legal Guardian Named Below					☐ email:							
I authorize NexgenRx Inc. (a) to use the personal information disclosed on this form, and any other personal information known to NexgenRx Inc. regarding the above-named patient, for the purpose of assessing this prior authorization request and any related claim and administering the benefit plan under which any such claim is made, and (b) to contact, and to obtain any such personal information from and to disclose any such personal information to, any physician, pharmacist or other health care professional having knowledge of such patient's health relevant to this request and any related claim.  Patient / Legal Guardian Name:												
Signature of Patient/ Legal Guardian:					Date (dd/mm/yy):							
Section 2: To be completed by Physician												
Drug Name & Strength:	DIN:		[	Dosage	Instructions:	uctions:						
Eligibility for drug coverage is dependent upon the patient meeting at least one of the qualifying criteria listed below. If the patient has another drug plan, prior authorization may cover some or all of the excess not paid by the primary plan.  Please indicate if the patient meets at least one of the following qualifying criteria for drug coverage:  In combination with methotrexate to reduce the signs and symptoms and improve physical function of moderate to severe active rheumatoid arthritis in adult patients.  To inhibit the progression of structural damage in adult patients with moderate to severe active rheumatoid arthritis in adults who have not been previously treated with methotrexate.  To reduce the signs and symptoms, inhibit the progression of structural damage and improve physical function in adults with moderate to severe active psoriatic arthritis. Simponi can be used in combination with methotrexate in patients who do not adequately respond to methotrexate along To treat adult patients, with moderate to severe active ulcerative colitis (UC), who have had an inadequate response, or have medical contraindications to, conventional therapy and for reducing signs and symptoms of UC and inducing sustained clinical remission.										n re		
Reducing signs and symptoms in adult patients with active Ankylosing Spondylitis who have had an inatherapies.							e response	e to conv	ventiona	ıl		
Physician Name: (Last, First)					License Number:							
Address: (Street, City, Province, Postal Code)					Telephone Number : ( ) - Fax Number: ( ) -							
Signature of Physician:						ate (dd/mm/yy)						
Section 3: To be completed by I	Pharmacist											
Pharmacy Name:						Provider	Number:					
Pharmacy Address: (Street, City, Province, Postal Code)							Telephone Number : ( ) -  Fax Number: ( ) -					
Signature of Pharmacist:						- ax inuii	IDGI.	( )	-			
Pharmacist's Name: (Print Last, First)												
Internal Office Use Only:												

Date Approved & By: